CMS (Chromosome)- Create and Develop A “Gene Passport” for Global Biogene Technology

CMS (Chromosome), a great undertaking that uses genetic technology to benefit human health, was born to solve these pain points, and have focused on the vertical field of blockchain & gene technology for a long time.

August 10, 2020 /PressReleaseAgency/ —

In 2013, Hollywood star Angelina Jolie Voight did a genetic test. The test results showed that there is a defective gene BRCA1 in her body, which will make her have an 87% chance of getting breast cancer and a 50% chance of getting ovarian cancer. After that, she decisively chose to remove the breast and ovaries to avoid the risk of cancer.

In 2004, Steve Jobs, one of the founders of Apple, was diagnosed with pancreatic cancer, doctors once stated that his chance of living a year was less than 10%. Through the interpretation of all his genes and tumor tissues, on which he spent about US$100,000, he learned about the unique genes and molecular characteristics of tumor. Since then, the medical team has re-developed a treatment plan for him, choosing specific drugs to reduce the frequency of cell cancerous molecules, allowing him to successfully extend his life for 7 years.

In 2006, Sergey Brin, one of the founders of Google, confirmed that his gene carries the same "LRRK2" mutant gene as his mother through genetic sequencing .The probability that makes him suffer from Parkinson's syndrome by carrying this gene is 55%-75%. In view of the results shown in the gene sequencing report, he began to change his life style by insisting on physical exercise and drinking green tea every day. Finally it successfully reduced his probability of suffering from Parkinson's to 10%.

But just this year, 58,000 Americans died from COVID-19 (likely at the low end), and more are currently sick who we will lose in the future. It all has to do with gene technology. According to the latest statistics from the World Health Organization, 4 million people die of diabetes each year; 9.6 million people die from cancer; and more than 15 million people die from cardiovascular and cerebrovascular diseases. At present, the precision medical industry, early screening, auxiliary diagnosis, and targeted therapy covered by gene sequencing is gradually taking shape. The health management needs of ancestral judgment, genetic disease risk assessment, and chronic disease prevention derived from the results of gene sequencing are also increasing.

·The Pain Points of Gene Sequencing
1.The data acquisition system is wanting in automation. Signing a contract, making payments and transferring data all require human labor to achieve, so it is very inefficient.
2.Genomic and phenotypic data usually come from different databases and are coded in different data formats. Standardizing these data is very time-consuming.
3.The existence of middlemen prevents buyers from directly communicating with data providers. Data purchased from middlemen often contains a lot of data that is useless to buyers.
4.The price of gene sequencing is relatively high. At present, the lowest price for personal whole-genome sequencing by an autonomous sequencing platform is $600. If 100 people in the experimental group and 100 people in the control group need to test the whole genome data, the cost is 120,000 US dollars.
5.Data mining is not comprehensive. A single institution is familiar with limited fields, and can often only start from the fields it is familiar with. If multiple teams can share data, the data will be more comprehensive.
6.Data sharing is difficult. On one hand, due to the large amount of genome sequencing data, a sample can be as small as a few GB or as many as hundreds of GB. When the sample size is large, the total data volume is often on the order of terabytes, making it difficult to transmit data quickly. On another hand, due to the high cost and value of genome sequencing data, some institutions have no incentive to share data except for the disclosure of data required by some publications.

And CMS (Chromosome), a great undertaking that uses genetic technology to benefit human health, was born to solve these pain points, and have focused on the vertical field of blockchain & gene technology for a long time.

Several experimental vaccines targeting COVID-19 are currently in clinical trials. Moderna, the maker of the vaccine mRNA-1273 says that their vaccine against the novel coronavirus COVID-19 may be available this fall to a select group of people.

However, the development of vaccines led by CMS (Chromosome) experts will be faster than Moderna’s team. Additionally, CMS(Chromosome) provides vaccine sales services through the platform and shares the sales revenue with users. Investors can obtain investment income from holding CMS(Chromosome) token, which provide more biomedical protection for their future health or for their family members.

Based on powerful blockchain technology, innovative business models, and unique token economy, CMS (Chromosome)is aiming to creating the world's largest comprehensive Genome phenotype data storage platform. Using genetic technology innovations to promote the development of global life sciences and promote the wide application in the fields of genetic technology and life and health, thereby creating huge commercial value and benefiting the healthy life of all mankind.

CMS (Chromosome) is an application chain centered on genome-wide phenotypic data storage, data operation analysis services, and scientific and technological health services. It brings a variety of ecological roles to enrich and improve the value chain of the CMS (Chromosome) token body. CMS (Chromosome) adopts the consensus mechanism of PoW+PoS, which is used to solve the problems of data value certification, certificate rights and interests, block maintenance and accounting, user incentive schemes, certificate circulation management, and sustainable ecological development.

Contact Info:
Name: Media Relations
Email: Send Email
Organization: BMDGE
Website: https://bmdge.com

Source: PressReleaseAgency

Release ID: 88972030